Prostate Cancer International is
for 2011 by Great NonProfits
Perspective Confidentiality Disclosure Reliability Courtesy
A new analysis of information from the Surveillance, Epidemiology and End Results (SEER) database suggests that the “hazard” for prostate cancer-specific mortality after radical prostatectomy is very low but that it does increase in a continuous manner for at least 15 years post-treatment.
Filed under: Living with Prostate Cancer, Management | Tagged: hazard, mortality, PCSM, prostate cancer-specific, radical prostatectomy, surgery | 6 Comments »
From 12:00 noon to 01:00 p.m. on Wednesday, December 7, the Men’s Health Caucus — Prostate Cancer Task Force and the Men’s Health Network will present “Prostate Cancer Screening: Dangerous or Life Saving?” (a lunch briefing about the controversy over screening for prostate cancer) in the Rayburn Building, B-340, on Capitol Hill in Washington, DC.
Filed under: Uncategorized | 24 Comments »
An article by Markert et al., just published on line in the Proceedings of the National Academy of Sciences, suggests that microarray analysis of messenger ribonucleic acid (mRNA) expression in prostate cancer tumors may be an independent indicator of the aggressiveness of prostate cancers in individual patients.
Filed under: Diagnosis, Management, Risk | Tagged: expression. signature, gene, mortality, outcome, profile, risk | 1 Comment »
A new article by Vickers, Roobol, and Lilja, scheduled for publication in the January 2012 issue of the Annual Review of Medicine is likely to raise some eyebrows in the urology community.
Filed under: Diagnosis, Management, Risk | Tagged: Management, risk, sc reening, stratification | 7 Comments »
The expertise of the pathologist assessing your prostate biopsy cores may make a major difference to the way you and your doctors think you need to be treated. Indeed the following data would suggest that many prostate biopsy samples should be examined by genitourinary pathologists who really specialize in prostate pathology.
Filed under: Diagnosis, Risk | Tagged: Gleason, pattern, under-diagnosis | 2 Comments »
A new report in Lancet Oncology offers guidance on which patients with prostate cancer who are initially treated with radiotherapy and 6 months of neoadjuvant androgen deprivation therapy (ADT) are at relatively high and relatively low levels of risk for prostate cancer-specific mortality.
Filed under: Diagnosis, Living with Prostate Cancer, Management, Risk, Treatment | Tagged: ADT, androgen deprivation, cancer-specific, marker, mortality, neoadjuvant, progression, PSA, radiation, surrogate | 2 Comments »
At the end of our 2010 Thanksgiving report we wrote, “we look forward to a similarly positive report a year from now — hopefully to include the approval of dutasteride in the prevention of prostate cancer and abiraterone acetate to extend the survival of men who have already stopped responding to docetaxel-based chemotherapy.”
Filed under: Diagnosis, Drugs in development, Living with Prostate Cancer, Management, Risk | Tagged: Thanksgiving | 3 Comments »
A commentary published in the October issue of the Journal of the National Cancer Institute addresses the question of whether the real failure of the use of screening processes for the early diagnosis of a variety of cancers has to do with public perceptions and professional and patient education.
Filed under: Diagnosis, Management, Risk | 2 Comments »
According to a media release issued by Celgene yesterday, the company has terminated the so-called MAINSAIL trial in the treatment of men with castration-resistant prostate cancer (CRPC).
Filed under: Drugs in development, Management | Leave a Comment »
An article in today’s New York Times (“‘Cancer’ or ‘weird cells’: which sounds deadlier?“) focuses on the question of whether many conditions currently referred to as “cancer” really are … and whether by calling them “cancer” we prejudice doctors and patients into taking overly aggressive action.
Filed under: Diagnosis, Living with Prostate Cancer, Risk | Tagged: breast, cancer, myeloma, name, prostate, risk | 9 Comments »
A new paper published by researchers from Sweden’s prestigious Karolinska Institute and related institutions makes it increasingly clear that — to date — we haven’t been able to work out (let alone consistently use) a really good way to measure real urinary continence after radical prostatectomy.
Filed under: Living with Prostate Cancer, Management | Tagged: accuracy, continence, incontinence, measurement | Leave a Comment »
An article published on line in the Journal of Urology last Friday suggests that an enzyme known as G-protein-coupled receptor kinase 5 or GRK5 may have an important role in the regulation of the growth of prostate cancer.
Filed under: Drugs in development | Tagged: G-protein, GRK5, kinase, receptor | Leave a Comment »
Two recent papers have reported data relevant to the application of high-dose, image-guided, intensity-modulated forms of radiation therapy (IGRT/IMRT) in the first-line treatment of men with localized prostate cancer.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: IGRT, image-guided, IMRT, intensity-modulated, radiation therapy, side effects, toxicity | 2 Comments »
In the October issue of European Urology there was an interesting “consensus statement” about the role of radiation therapy as adjuvant or salvage therapy for men who are at significant risk for recurrence of their prostate cancer after first-line treatment with radical prostatectomy.
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: "high risk", adjuvant, post-surgery, radiation therapy, salvage | 1 Comment »
Search for new and
ongoing trials on the
CTAG PCa web site